Journal for immunotherapy of cancer

2026

DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.

doi:10.1136/jitc-2025-012805 ·PMID:41672597

BackgroundDual anti-CTLA-4/PD-1 inhibitors show efficacy in numerous malignancies. We are the first to report on the efficacy of ipilimumab-nivolumab immunotherapy in a dedicated cohort of patients with gynecologic clear cell carcinomas (CC…

2026

VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.

doi:10.1136/jitc-2026-014991 ·PMID:42336655

PurposeLiver metastases (LMs) confer resistance to immune checkpoint blockade in advanced non-squamous non-small cell lung cancer (ns-NSCLC), likely through an immunosuppressive tumor microenvironment (TME). We hypothesized that vascular en…

2024

Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and accelerates immunotherapy.

doi:10.1136/jitc-2023-008441 ·PMID:39089738

BackgroundEnhanced glucose metabolism has been reported in many cancers. Glucose-6-phosphate dehydrogenase (G6PD) is a rate-limiting enzyme involved in the pentose phosphate pathway, which maintains NADPH levels and protects cells from oxid…

2024

Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.

doi:10.1136/jitc-2024-009262 ·PMID:39053945

BackgroundImmunosuppressive conditions within the tumor microenvironment (TME) can allow tumors to evade the immune system, including by hampering programmed death ligand 1 (PD-L1) inhibitor activity. Interleukin (IL)-8 contributes to immun…